Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole.
about
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trialAspergillus mastoiditis in a patient with systemic lupus erythematosus: a case reportGeneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots.Phase II dose escalation study of caspofungin for invasive Aspergillosis.Safety and potential of drug interactions of caspofungin and voriconazole in multimorbid patients.Drug-drug interactions of antifungal agents and implications for patient care.Voriconazole in the treatment of fungal osteomyelitis of the orbit in the immunocompromised host.Population pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosisResistance to echinocandin-class antifungal drugs.Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology.Short native antimicrobial peptides and engineered ultrashort lipopeptides: similarities and differences in cell specificities and modes of action.Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.Physiology-based pharmacokinetics of caspofungin for adults and paediatrics.Lack of pharmacokinetic interaction between anidulafungin and tacrolimus.Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections.Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study.Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders.Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis.Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease.Candida krusei fungemia in an unrelated allogeneic hematopoietic stem cell transplant patient successfully treated with Caspofungin.Breakthrough Candida infections in patients receiving voriconazole.Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers.Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies.Successful treatment of aspergillus brain abscess in a child with acute lymphoblastic leukemia and liver failure.In vitro assessment of non-irritant microemulsified voriconazole hydrogel system.Echinocandins for management of invasive candidiasis in patients with liver disease and liver transplantation.Management of bacterial and fungal infections in end stage liver disease and liver transplantation: Current options and future directions
P2860
Q28277029-18B05F4A-D2E2-43AD-8EE2-DA787606774CQ33854124-FA7ED9EE-E498-4950-A253-318BC09F7217Q34116690-113A1144-F5DC-4B4F-9006-B68239E8C3F2Q35598439-CAD81B48-DC04-4787-901A-6F530B88AB40Q36271648-EAF3C7A5-0E5E-4AC0-BB47-B50333BA9C1AQ36283721-1C1A19F4-7F53-4D91-AB65-98C706AF49E1Q36342105-8119A67A-4498-4993-A6BE-20C05488B62DQ36757591-44E3ED12-C54C-4990-AE04-8B285043656EQ36849595-B04AE9E9-FCCB-43CB-BAC8-1FD063B5CD3AQ37344532-3D9998B1-4A8A-4241-856A-404F8BB0C921Q37875765-EBBF140E-29EB-40A4-9B65-C91736558A41Q38681635-9AF54E6A-A635-43A4-86E1-34C7E4ABB42DQ41671785-3ACF967C-1066-4B5A-907B-B5D9FABF69D9Q42612968-2E21CBB2-1B87-4368-B0FC-C1C862D08D2EQ42686004-8520FC0D-B893-4D39-8D31-FB5FD02338B4Q43198289-2CE19C3C-EE8E-40C7-97C7-5C7346EE2717Q43468516-BE6A54CE-F289-4E61-B4E2-C157BA6C52CCQ44925292-A4109FE6-7A9B-4987-B0E4-EE5EEB2FB2FAQ45221750-6871B8C1-7E83-4DA6-98E9-9CB932507BEEQ46455747-28B13088-BE31-497B-9474-E826738C19E6Q46508204-9E242932-D869-4B35-927B-FE05C44EE82AQ46650423-A041270A-753F-4001-B1B6-3CD2237CD424Q46653990-AB681AA1-A73E-4BAF-9052-6467BAD3A589Q46775949-2822FD4B-8673-461F-BA72-C1421B81EF4DQ52820816-90BA106E-0C41-4C8E-803D-CEA9D64039C6Q54957028-44C1F787-143C-4A93-BAD5-0A31DE5B8C4AQ57815117-103D038F-3267-4222-97B0-47AA5B6E34E1
P2860
Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Review of the safety, tolerabi ...... caspofungin and voriconazole.
@ast
Review of the safety, tolerabi ...... caspofungin and voriconazole.
@en
type
label
Review of the safety, tolerabi ...... caspofungin and voriconazole.
@ast
Review of the safety, tolerabi ...... caspofungin and voriconazole.
@en
prefLabel
Review of the safety, tolerabi ...... caspofungin and voriconazole.
@ast
Review of the safety, tolerabi ...... caspofungin and voriconazole.
@en
P1476
Review of the safety, tolerabi ...... caspofungin and voriconazole.
@en
P2093
Andrew J Ullmann
P304
P356
10.1185/030079903125001884
P407
P577
2003-01-01T00:00:00Z